Blue Jet Healthcare Limited announces Q2 and H1 FY2027 unaudited financial results
Blue Jet Healthcare · Pharmaceuticals & Biotechnology
Key highlights
- Board approved unaudited standalone financial results for quarter and half year ended Sept 30, 2026, on Nov 5, 2026
- Company allotted 1.58 crore equity shares at ₹506 each via Qualified Institutional Placement, raising ₹800 crore
- Profit before tax for H1 FY2027 was ₹2433.40 million; EPS for H1 was ₹10.00 per share (face value ₹2 each)
Why it's rated major development: the year-on-year change is 97% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E, Thursday, November 5, 2026.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Blue Jet Healthcare
- Financial resultsMajor developmentBlue Jet Healthcare announces unaudited results for quarter ended September 30, 2026
Other fundraise / allotment filings this fortnight
- Arvaya Healthcare Limited revises Rights Issue committee authorisation details
- Sellwin Traders Limited converts 77.05 lakh warrants into equity shares on Nov 5, 2026
- Emerald Leisures Ltd files Draft Letter of Offer for proposed Rights Issue
- Ceigall India approves Q2 results, up to Rs. 1000 Crores fundraise, subsidiary sale offer
- Ceigall India Sep-26 quarter profit Rs 921.67 mn; board approves Rs 1000 crore raise
- Ceigall India: Q2 results, Rs. 1000 crore fund raise plan, subsidiary sale offer
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.